Clinical Report: Oncology Networks and Organizations within Medicare Advantage Programs
Overview
This report evaluates the structure and effectiveness of oncology networks within Medicare Advantage (MA) plans, highlighting limitations in access to comprehensive cancer care. A substantial proportion of MA plans restrict access to National Cancer Institute-designated centers.
Background
The growth of Medicare Advantage plans has surpassed Traditional Medicare, now covering over half of all beneficiaries. MA plans utilize capitated payments, which can incentivize cost-containment strategies that may restrict access to necessary oncology services.
Data Highlights
This study analyzed data from 807,580 beneficiaries diagnosed with various cancers from 2010 to 2019, focusing on trends in oncology networks under MA plans from 2016 to 2019.
Key Findings
41% of MA plans exclude NCI-designated comprehensive cancer centers from their networks.
30.5% of MA beneficiaries have plans with narrow networks for primary care.
43.1% of MA beneficiaries have narrow networks for psychiatry.
83.2% of MA beneficiaries have narrow networks for mental and behavioral health.
Average MA plans include fewer than half of physicians nationwide.
Directory-based analyses may misrepresent actual access to oncology services.
Clinical Implications
Healthcare providers should be aware of limitations in access to oncology services for patients enrolled in MA plans.
Conclusion
The findings indicate the need for ongoing evaluation of oncology networks within Medicare Advantage plans.
The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement
